Capillary action migrates the resultant complex along the strip, where it binds a second set of virus-specific antibodies, attached to the result line area. This second binding, with the ...

Kennedy's move appears to shortcut the CDC's outside vaccine advisers, dropping COVID vaccines from the list recommended for ...

Adults hospitalized for RSV face higher odds of cardiac complications than those with COVID-19 or influenza, especially in ...

A single dose of the long-acting antibody nirsevimab developed to prevent respiratory syncytial virus infections (The drug ...

Respiratory syncytial virus (RSV) is the most important cause of infantile bronchiolitis and pneumonia. It is ubiquitous, with most children acquiring their primary infection within the first year ...

The incidence of RSV across 5 respiratory virus seasons was substantial among adult patients with high-risk underlying conditions.

When an RSV vaccine became available for use during pregnancy, it offered a natural experiment between various countries to ...

Respiratory Syncytial Virus (RSV) poses a significant threat to Indian infants, particularly during post-monsoon and winter, ...

Adults with RSV-associated acute respiratory infection face a 2.7-fold higher risk for death within one year, according to a ...

RSV prevention products led to a significant reduction in hospitalization rates for infants aged 0 to 7 months during the 2024-2025 season. The maternal RSV vaccine and nirsevimab were key ...

Last winter’s respiratory syncytial virus, or RSV, season wasn’t as brutal for U.S. babies. A new study suggests two preventive tools — a maternal vaccine and a monoclonal antibody for ...